FAQ/Help |
Calendar |
Search |
Today's Posts |
06-18-2020, 03:52 PM | #1 | |||
|
||||
Senior Member
|
This article from Medscape Today (June 5, 2020) indicates that the new oral disease-modifying treatments for MS haven't been as popular as they were expected to be--and Ocrevus seems to be the favorite DMT--"Newest oral DMTs haven't yet made a big impact in the MS world":
Newest Oral DMTs Haven't Yet Made a Big Impact in the MS World
__________________
Repeal the law of gravity! MS diagnosed 1980. Type 2 diabetes, osteoarthritis, osteopenia. Avonex 2002-2005. Copaxone 6/4/07-5/15/10. Currently: Glatopa (generic Copaxone), 40mg 3 times/week, 12/16/20 - 3/16/24 |
|||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||